RE: Snippet25 Nov 2025 11:26
Well, there are already a lot of brands selling Fruitflow products, a modest increase in their volumes could see us in to profit.
From next year, DSM's cut disappears, this again goes to the bottom line.
Next up (we assume) ByHealth will launch multiple products based on BlueCap approval, they are well versed in major promotions in their market. Size of market take up is always debateable, but, added to existing revenue streams, they should push us in to strong profit and cashflows which could see the board deciding to buy up shares for cancellation.
Then, and this is further away, DSM make headway with the gut biome technology. opening the way for a whole new revenue stream.
Four strong positives.
Set against that the perennial issues that seem to obsess too many folks, lack of comms, and poor performance from the AIM market.